February 3, 2024 06:00 AM EST

End of Aduhelm’s road; Janet Woodcock exit interview; Stuart Schreiber's $500M experiment; Vertex's pain breakthrough; and more

Amber Tong

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

End of Aduhelm’s road; Janet Woodcock exit interview; Stuart Schreiber's $500M experiment; Vertex's pain breakthrough; and more

Amber Tong

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

End of Aduhelm’s road; Janet Wood­cock ex­it in­ter­view; Stu­art Schreiber's $500M ex­per­i­ment; Ver­tex's pain break­through; and more

Amber Tong

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

End of Aduhelm’s road; Janet Woodcock exit interview; Stuart Schreiber's $500M experiment; Vertex's pain breakthrough; and more

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties